Literature DB >> 17296751

A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity.

Shite Sebastian1, Simon T Dillon, Jillian G Lynch, LeeAnn T Blalock, Emmy Balon, Kristin T Lee, Laurie E Comstock, J Wayne Conlan, Eric J Rubin, Arthur O Tzianabos, Dennis L Kasper.   

Abstract

Francisella tularensis, the causative agent of tularemia, has been designated a CDC category A select agent because of its low infective dose (<10 CFU), its ready transmission by aerosol, and its ability to produce severe morbidity and high mortality. The identification and characterization of this organism's virulence determinants will facilitate the development of a safe and effective vaccine. We report that inactivation of the wbtA-encoded dehydratase of the O-antigen polysaccharide (O-PS) locus of the still-unlicensed live vaccine strain of F. tularensis (LVS) results in a mutant (the LVS wbtA mutant) with remarkably attenuated virulence. Western blot analysis and immune electron microscopy studies associate this loss of virulence with a complete lack of surface O-PS expression. A likely mechanism for attenuation is shown to be the transformation from serum resistance in the wild-type strain to serum sensitivity in the mutant. Despite this significant attenuation in virulence, the LVS wbtA mutant remains immunogenic and confers protective immunity on mice against challenge with an otherwise lethal dose of either F. tularensis LVS or a fully virulent clinical isolate of F. tularensis type B. Recognition and characterization of the pivotal role of O-PS in the virulence of this intracellular bacterial pathogen may have broad implications for the creation of a safe and efficacious vaccine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296751      PMCID: PMC1865767          DOI: 10.1128/IAI.01789-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.

Authors:  R M Horton; H D Hunt; S N Ho; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

2.  Mice intradermally-inoculated with the intact lipopolysaccharide, but not the lipid A or O-chain, from Francisella tularensis LVS rapidly acquire varying degrees of enhanced resistance against systemic or aerogenic challenge with virulent strains of the pathogen.

Authors:  J Wayne Conlan; Evguenii Vinogradov; Mario A Monteiro; Malcolm B Perry
Journal:  Microb Pathog       Date:  2003-01       Impact factor: 3.738

3.  A capsule-deficient mutant of Francisella tularensis LVS exhibits enhanced sensitivity to killing by serum but diminished sensitivity to killing by polymorphonuclear leukocytes.

Authors:  G Sandström; S Löfgren; A Tärnvik
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

4.  Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis.

Authors:  Joann L Prior; Richard G Prior; Paul G Hitchen; Helen Diaper; Kate F Griffin; Howard R Morris; Anne Dell; Richard W Titball
Journal:  J Med Microbiol       Date:  2003-10       Impact factor: 2.472

5.  Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies.

Authors:  J Wayne Conlan; Wangxue Chen; Hua Shen; Ann Webb; Rhonda KuoLee
Journal:  Microb Pathog       Date:  2003-05       Impact factor: 3.738

6.  Gonococci causing disseminated gonococcal infection are resistant to the bactericidal action of normal human sera.

Authors:  G K Schoolnik; T M Buchanan; K K Holmes
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

Review 7.  Nature of protective immunity to Francisella tularensis.

Authors:  A Tärnvik
Journal:  Rev Infect Dis       Date:  1989 May-Jun

8.  A Francisella tularensis pathogenicity island required for intramacrophage growth.

Authors:  Francis E Nano; Na Zhang; Siobhán C Cowley; Karl E Klose; Karen K M Cheung; Michael J Roberts; Jagjit S Ludu; Gregg W Letendre; Anda I Meierovics; Gwen Stephens; Karen L Elkins
Journal:  J Bacteriol       Date:  2004-10       Impact factor: 3.490

9.  MglA regulates transcription of virulence factors necessary for Francisella tularensis intraamoebae and intramacrophage survival.

Authors:  Crystal M Lauriano; Jeffrey R Barker; Sang-Sun Yoon; Francis E Nano; Bernard P Arulanandam; Daniel J Hassett; Karl E Klose
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-09       Impact factor: 11.205

10.  Multiple T cell subsets control Francisella tularensis LVS intracellular growth without stimulation through macrophage interferon gamma receptors.

Authors:  Siobhán C Cowley; Karen L Elkins
Journal:  J Exp Med       Date:  2003-07-28       Impact factor: 14.307

View more
  48 in total

1.  Francisella tularensis Schu S4 O-antigen and capsule biosynthesis gene mutants induce early cell death in human macrophages.

Authors:  Stephen R Lindemann; Kaitian Peng; Matthew E Long; Jason R Hunt; Michael A Apicella; Denise M Monack; Lee-Ann H Allen; Bradley D Jones
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.

Authors:  Qingmei Jia; Bai-Yu Lee; Richard Bowen; Barbara Jane Dillon; Susan M Som; Marcus A Horwitz
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

3.  Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies.

Authors:  Taylor C Stevenson; Colette Cywes-Bentley; Tyler D Moeller; Kevin B Weyant; David Putnam; Yung-Fu Chang; Bradley D Jones; Gerald B Pier; Matthew P DeLisa
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-19       Impact factor: 11.205

4.  Identification of an essential Francisella tularensis subsp. tularensis virulence factor.

Authors:  Aiping Qin; David W Scott; Jennifer A Thompson; Barbara J Mann
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

5.  O antigen protects Bordetella parapertussis from complement.

Authors:  Elizabeth M Goebel; Daniel N Wolfe; Kelly Elder; Scott Stibitz; Eric T Harvill
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

6.  Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.

Authors:  Heather J Ray; Yu Cong; Ashlesh K Murthy; Dale M Selby; Karl E Klose; Jeffrey R Barker; M Neal Guentzel; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-02-11

Review 7.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

8.  Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis.

Authors:  Ryan M Troyer; Katie L Propst; Jeff Fairman; Catherine M Bosio; Steven W Dow
Journal:  Vaccine       Date:  2009-05-31       Impact factor: 3.641

9.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

10.  Small molecule control of virulence gene expression in Francisella tularensis.

Authors:  James C Charity; Leeann T Blalock; Michelle M Costante-Hamm; Dennis L Kasper; Simon L Dove
Journal:  PLoS Pathog       Date:  2009-10-30       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.